Radiotherapy with continued EGFR‐TKIs for oligoprogressive disease in EGFR‐mutated non‐small cell lung cancer: A real‐world study

BACKGROUND: Epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) develops resistance to tyrosine kinase inhibitors (TKIs). Here, we evaluated the efficacy of radiotherapy and continuation of TKIs in patients with advanced NSCLC with oligoprogression after EGFR‐TKIs. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Chunhong, Wu, Sixuan, Deng, Renfang, Wu, Yuanqiang, Pan, Yue, Shu, Long, Wu, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844634/
https://www.ncbi.nlm.nih.gov/pubmed/35666038
http://dx.doi.org/10.1002/cam4.4894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844634/
https://www.ncbi.nlm.nih.gov/pubmed/35666038
http://dx.doi.org/10.1002/cam4.4894

Ejemplares similares